Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China
· Delayed Price · Currency is CNY 11.24
-0.02 (-0.18%)
Apr 29, 2026, 3:04 PM CST
Yifan Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 355.69 | 402.02 | 385.97 | -551.07 | 191.22 | 278.4 | Upgrade
|
| Depreciation & Amortization | 344.12 | 344.12 | 335.67 | 270.6 | 228.43 | 207.18 | Upgrade
|
| Other Amortization | 18.16 | 18.16 | 9.93 | 9.21 | 9.48 | 6.88 | Upgrade
|
| Loss (Gain) From Sale of Assets | -12.7 | -12.7 | -30.15 | -2.57 | 0.56 | -14.83 | Upgrade
|
| Asset Writedown & Restructuring Costs | 30.37 | 30.37 | 73.69 | 872.46 | 102.13 | 38.25 | Upgrade
|
| Loss (Gain) From Sale of Investments | 27.31 | 27.31 | 14.16 | 15.06 | 17.63 | 4.49 | Upgrade
|
| Provision & Write-off of Bad Debts | 22.75 | 22.75 | 61.63 | 60.47 | 29.12 | 21.34 | Upgrade
|
| Other Operating Activities | 203.34 | 54.51 | 37 | -237.89 | 38.44 | 56.52 | Upgrade
|
| Change in Accounts Receivable | -109.04 | -109.04 | -363.72 | -10.25 | -103.77 | -18.59 | Upgrade
|
| Change in Inventory | -202.11 | -202.11 | -147.75 | -109.39 | -167.1 | -80.48 | Upgrade
|
| Change in Accounts Payable | -115.23 | -115.23 | 239.99 | 62.88 | 156.63 | -99.34 | Upgrade
|
| Change in Other Net Operating Assets | 18.05 | 18.05 | 19.71 | 21.79 | 23.15 | -10.3 | Upgrade
|
| Operating Cash Flow | 560.87 | 458.37 | 640.73 | 348.58 | 472.07 | 301.23 | Upgrade
|
| Operating Cash Flow Growth | -12.67% | -28.46% | 83.81% | -26.16% | 56.71% | -72.82% | Upgrade
|
| Capital Expenditures | -663.77 | -559.23 | -628.16 | -504.09 | -542.27 | -571.74 | Upgrade
|
| Sale of Property, Plant & Equipment | 29.59 | 24.41 | 0.32 | 5.02 | 7.84 | 17.7 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | -42 | Upgrade
|
| Divestitures | - | - | 5.29 | 1.06 | 1.2 | 15.9 | Upgrade
|
| Investment in Securities | 80.59 | 80.59 | 75 | -39.13 | -137.58 | 66.6 | Upgrade
|
| Other Investing Activities | 0.14 | 0.13 | 2.67 | 4.3 | 0.65 | 5.64 | Upgrade
|
| Investing Cash Flow | -553.45 | -454.09 | -544.88 | -532.84 | -670.17 | -507.89 | Upgrade
|
| Long-Term Debt Issued | - | 1,857 | 2,001 | 1,855 | 1,789 | 2,928 | Upgrade
|
| Long-Term Debt Repaid | - | -1,800 | -1,709 | -2,044 | -1,897 | -2,448 | Upgrade
|
| Net Debt Issued (Repaid) | 144.66 | 57.38 | 291.87 | -189.38 | -107.72 | 480.27 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 0.85 | 1 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -38 | -53.56 | -121.47 | Upgrade
|
| Common Dividends Paid | -170.99 | -171.58 | -194.81 | -72.47 | -86.38 | -138.39 | Upgrade
|
| Other Financing Activities | 1.35 | 0.03 | 15.67 | 330.62 | 234.15 | 0.75 | Upgrade
|
| Financing Cash Flow | -24.98 | -114.17 | 112.73 | 30.78 | -12.66 | 222.16 | Upgrade
|
| Foreign Exchange Rate Adjustments | -20.54 | -3.97 | -3.69 | 14.59 | 59.56 | -20.85 | Upgrade
|
| Net Cash Flow | -38.11 | -113.87 | 204.89 | -138.88 | -151.2 | -5.36 | Upgrade
|
| Free Cash Flow | -102.9 | -100.87 | 12.57 | -155.5 | -70.21 | -270.51 | Upgrade
|
| Free Cash Flow Margin | -2.03% | -1.97% | 0.24% | -3.82% | -1.83% | -6.13% | Upgrade
|
| Free Cash Flow Per Share | -0.08 | -0.08 | 0.01 | -0.13 | -0.06 | -0.22 | Upgrade
|
| Cash Income Tax Paid | 288.37 | 368.39 | 321.69 | 362.22 | 91.5 | 220.66 | Upgrade
|
| Levered Free Cash Flow | -169.13 | -56.37 | -194.58 | -168.05 | -347 | -430.33 | Upgrade
|
| Unlevered Free Cash Flow | -137 | -23.22 | -151.39 | -120.83 | -293.35 | -383.71 | Upgrade
|
| Change in Working Capital | -428.18 | -428.18 | -247.18 | -87.68 | -144.96 | -295.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.